Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06076499 · ClinicalTrials.gov registry record
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
A clinical trial of Restless Legs Syndrome, sponsored by Noctrix Health.
- Active
- Registry status
- 325
- Enrollment target
- 6
- Study locations
NCT06076499 is a study of Restless Legs Syndrome that is active but no longer recruiting, run by Noctrix Health. The registered enrollment target is 325 participants, above the 73-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (345% higher). The trial reports 6 study locations across 5 states.
The verdict
NCT06076499, a study of Restless Legs Syndrome, is active but no longer recruiting, sponsored by Noctrix Health.
- ACTIVE NOT RECRUITING
- Registry status
- 325 participants
- Enrollment target
- 6
- Study locations
Study Summary
Multi-center post-market, observational study to assess the long-term effectiveness and safety of the NTX100 TOMAC System for patients with Restless Legs Syndrome.
Conditions Studied
Interventions
- DEVICE NTX100
Study Locations (6)
California
- Mark J Buchfuhrer, MD Office - Downey
- Sleep Medicine Specialists of California - San Ramon
Massachusetts
- Neurocare, Inc. - Newton
Missouri
- Clayton Sleep Institute - St Louis
Ohio
- Ohio Sleep Medicine and Institute - Dublin
South Carolina
- Bogan Sleep Consultants, LLC - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06076499
The ClinicalTrials.gov registry entry for NCT06076499 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 73-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (345% higher). The listed sponsor is Noctrix Health, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which NTX100 is the first listed.
NCT06076499 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT06076499 about?
NCT06076499 is a clinical study titled "A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS". Multi-center post-market, observational study to assess the long-term effectiveness and safety of the NTX100 TOMAC System for patients with Restless Legs Syndrome.
What is the current status of trial NCT06076499?
This trial is currently active not recruiting. The enrollment target is 325 participants. The study started on 2023-11-15. Estimated completion is 2026-12.
What conditions does trial NCT06076499 study?
This clinical trial studies the following conditions: Restless Legs Syndrome.
What interventions are being tested in trial NCT06076499?
The interventions under investigation include: NTX100 (DEVICE).
Who is sponsoring clinical trial NCT06076499?
This trial is sponsored by Noctrix Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06076499 being conducted?
This trial has 6 study locations across California, Massachusetts, Missouri, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
COMPLETED · Phase 1
-
A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.